Navigation Links
CLAAD Lauds Signature Therapeutics' R&D Efforts To Reduce Prescription Drug Abuse
Date:7/12/2013

WASHINGTON, July 12, 2013 /PRNewswire-USNewswire/ -- The Center for Lawful Access and Abuse Deterrence (CLAAD) praised Signature Therapeutics, Inc. today for taking a national lead in biopharmaceutical research and development to reduce prescription drug abuse. Signature Therapeutics is a privately held company developing next-generation abuse-deterrent prescription medications. 

More than 2.7 percent of the U.S. population currently abuses prescription drugs.[1] In 2010, prescription drug overdoses took the lives of 22,134 Americans.[2] Since 2009, CLAAD has called for private-sector research into novel technologies to reduce prescription drug abuse. 

Michael Barnes, executive director of CLAAD, said, "Signature Therapeutics has distinguished itself in a growing market for safer medications by thinking big."

Signature Therapeutics is creating novel innovations, including "prodrugs," which would resist common methods of drug abuse, such as melting and injecting, crushing and snorting, or chewing before swallowing.  The company's pills are designed to be bioactivated, meaning that when taken by mouth, enzymes in the gastrointestinal tract trigger the release of the active ingredient.  Administered in any other way, a pill would not produce euphoria or any other significant effect.

Signature Therapeutics intends to apply its prodrug technology beyond opioids to other classes of commonly abused medications that lack safety features, such as stimulants used to treat attention-deficit disorder. Opioid pain relievers are the most commonly abused prescription drugs, but the abuse of tranquilizers, stimulants, and sedatives is also harmful and prevalent.[3]  In 2011, the anti-anxiety medication alprazolam was the most commonly found drug in overdose cases in Georgia, according to an analysis of autopsies.[4]  A study at the University of Kentucky found that out of 1,811 undergraduates, 34 percent reported improper use of stimulants.[5]

"Signature Therapeutics is the only company that I am aware of that is developing abuse-deterrent medications in a variety of drug classes," Barnes said.

Wes Sterman, CEO of Signature Therapeutics, said, "We are thrilled that CLAAD has recognized our commitment to raising the bar for abuse resistance."

About the Center for Lawful Access and Abuse Deterrence
CLAAD coordinates efforts to prevent prescription drug fraud, diversion, and abuse while advancing patient access to high-quality medical care. Follow @claad_coalition.

About Signature Therapeutics, Inc.
Signature Therapeutics is a privately-held biopharmaceutical company focused on creating best-in-class abuse-resistant prescription medications.


[1] http://www.drugabuse.gov/publications/topics-in-brief/prescription-drug-abuse
[2] http://www.cdc.gov/media/releases/2013/p0220_drug_overdose_deaths.html
[3] http://www.drugabuse.gov/publications/topics-in-brief/prescription-drug-abuse
[4] http://www.mcduffieprogress.com/article_4607.shtml
[5] http://www.schumer.senate.gov/record.cfm?id=344041  


'/>"/>
SOURCE CLAAD
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CLAAD Petitions FDA To Reject Opioid Medications Without Safety Features
2. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
3. CLAAD Selects Egalet As Top Five Technologies To Reduce Prescription Drug Abuse Honoree
4. CLAAD Recognizes The Locking Cap as Top 5 Technology To Reduce Rx Abuse
5. CLAAD Recognizes SMART/Script as Top 5 Technology To Reduce Rx Abuse
6. CLAAD Highlights 5 Technologies To Reduce Prescription Drug Abuse
7. CLAAD Names Eagle Advancement Institute as Honoree of Top 5 Technologies To Reduce Prescription Drug Abuse
8. CLAAD Warns of Increase in Prescription Drug Overdoses
9. CHPA Applauds Pennsylvanias Adoption of Real-Time, Stop-Sale Technology, An Effective Tool in the Fight Against Methamphetamine
10. PPTA Applauds Preserving Access to Orphan Drugs Acts
11. CHPA Lauds Vermonts Adoption of HB 522
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , February 10, 2016 ... new market research report "Pharmaceutical Packaging Equipment Market by ... Labeling & Serialization), by Product Type (Tablet, Powder, Cream, ... published by MarketsandMarkets, studies the global market during the forecast ... to grow at a CAGR of 6.9% during the ...
(Date:2/10/2016)... , Feb. 9, 2016 On ... Administration (FDA) met with its Arthritis Advisory ... biosimilar of Johnson & Johnson,s Remicade and ... approved in the U.S. The Biologics Prescribers ... groups - Alliance for Patient Access, American ...
(Date:2/10/2016)... , February 10, 2016 ... Medicine, Targeted Therapeutics and Companion Diagnostic Market to ... Participants, and Environment" research report indicates that the ... $149 billion by 2020 growing at a CAGR ... companion diagnostics and targeted therapeutics and is dominated ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... ... As part of its ongoing series of aquatic therapy related webinars, HydroWorx ... dynamic expert and thoughtful presentation to give attendees a better sense of how to ... free to attend, but registration is required. , Rehabilitation of Offensive Lineman ...
(Date:2/10/2016)... Glendale, CA (PRWEB) , ... February 10, 2016 , ... ... can be harder to find. Unfortunately, this can leave patients with dental emergencies at ... Glendale , is now offering emergency dental care. , Common dental emergencies include:, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 ... more than 200 of the country’s top healthcare executives to share insights on ... benefit of the Forum is the provider-centric perspective, experience, expertise and strategy shared ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: ... winner and inspirational speaker Jan Fox will serve as keynote speaker at the ... provide participants with tools to more effectively communicate with their own organizational staff ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined ... readily available to physicians. The integration will enable Allscripts users to post open ... Everseat’s free mobile app. , The partnership gives Everseat substantial added power to ...
Breaking Medicine News(10 mins):